Targeting the NLRP3 inflammasome signalling for the management of atrial fibrillation

Research output: Contribution to journal › Review › Research › peer-review

Standard

Targeting the NLRP3 inflammasome signalling for the management of atrial fibrillation. / Niskala, Alisha; Heijman, Jordi; Dobrev, Dobromir; Jespersen, Thomas; Saljic, Arnela.

In: British Journal of Pharmacology, 2024.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Niskala, A, Heijman, J, Dobrev, D, Jespersen, T & Saljic, A 2024, 'Targeting the NLRP3 inflammasome signalling for the management of atrial fibrillation', British Journal of Pharmacology. https://doi.org/10.1111/bph.16470

APA

Niskala, A., Heijman, J., Dobrev, D., Jespersen, T., & Saljic, A. (2024). Targeting the NLRP3 inflammasome signalling for the management of atrial fibrillation. British Journal of Pharmacology. https://doi.org/10.1111/bph.16470

Vancouver

Niskala A, Heijman J, Dobrev D, Jespersen T, Saljic A. Targeting the NLRP3 inflammasome signalling for the management of atrial fibrillation. British Journal of Pharmacology. 2024. https://doi.org/10.1111/bph.16470

Author

Niskala, Alisha ; Heijman, Jordi ; Dobrev, Dobromir ; Jespersen, Thomas ; Saljic, Arnela. / Targeting the NLRP3 inflammasome signalling for the management of atrial fibrillation. In: British Journal of Pharmacology. 2024.

Bibtex

@article{0d7d7a24673b4fe5b0bb28e7999e105a,
title = "Targeting the NLRP3 inflammasome signalling for the management of atrial fibrillation",
abstract = "Inflammatory signalling via the nod-like receptor (NLR) family pyrin domain-containing protein-3 (NLRP3) inflammasome has recently been implicated in the pathophysiology of atrial fibrillation (AF). However, the precise role of the NLRP3 inflammasome in various cardiac cell types is poorly understood. Targeting components or products of the inflammasome and preventing their proinflammatory consequences may constitute novel therapeutic treatment strategies for AF. In this review, we summarise the current understanding of the role of the inflammasome in AF pathogenesis. We first review the NLRP3 inflammasome pathway and inflammatory signalling in cardiomyocytes, (myo)fibroblasts and immune cells, such as neutrophils, macrophages and monocytes. Because numerous compounds targeting NLRP3 signalling are currently in preclinical development, or undergoing clinical evaluation for other indications than AF, we subsequently review known therapeutics, such as colchicine and canakinumab, targeting the NLRP3 inflammasome and evaluate their potential for treating AF.",
author = "Alisha Niskala and Jordi Heijman and Dobromir Dobrev and Thomas Jespersen and Arnela Saljic",
note = "Publisher Copyright: {\textcopyright} 2024 The Author(s). British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.",
year = "2024",
doi = "10.1111/bph.16470",
language = "English",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley",

}

RIS

TY - JOUR

T1 - Targeting the NLRP3 inflammasome signalling for the management of atrial fibrillation

AU - Niskala, Alisha

AU - Heijman, Jordi

AU - Dobrev, Dobromir

AU - Jespersen, Thomas

AU - Saljic, Arnela

N1 - Publisher Copyright: © 2024 The Author(s). British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.

PY - 2024

Y1 - 2024

N2 - Inflammatory signalling via the nod-like receptor (NLR) family pyrin domain-containing protein-3 (NLRP3) inflammasome has recently been implicated in the pathophysiology of atrial fibrillation (AF). However, the precise role of the NLRP3 inflammasome in various cardiac cell types is poorly understood. Targeting components or products of the inflammasome and preventing their proinflammatory consequences may constitute novel therapeutic treatment strategies for AF. In this review, we summarise the current understanding of the role of the inflammasome in AF pathogenesis. We first review the NLRP3 inflammasome pathway and inflammatory signalling in cardiomyocytes, (myo)fibroblasts and immune cells, such as neutrophils, macrophages and monocytes. Because numerous compounds targeting NLRP3 signalling are currently in preclinical development, or undergoing clinical evaluation for other indications than AF, we subsequently review known therapeutics, such as colchicine and canakinumab, targeting the NLRP3 inflammasome and evaluate their potential for treating AF.

AB - Inflammatory signalling via the nod-like receptor (NLR) family pyrin domain-containing protein-3 (NLRP3) inflammasome has recently been implicated in the pathophysiology of atrial fibrillation (AF). However, the precise role of the NLRP3 inflammasome in various cardiac cell types is poorly understood. Targeting components or products of the inflammasome and preventing their proinflammatory consequences may constitute novel therapeutic treatment strategies for AF. In this review, we summarise the current understanding of the role of the inflammasome in AF pathogenesis. We first review the NLRP3 inflammasome pathway and inflammatory signalling in cardiomyocytes, (myo)fibroblasts and immune cells, such as neutrophils, macrophages and monocytes. Because numerous compounds targeting NLRP3 signalling are currently in preclinical development, or undergoing clinical evaluation for other indications than AF, we subsequently review known therapeutics, such as colchicine and canakinumab, targeting the NLRP3 inflammasome and evaluate their potential for treating AF.

UR - http://www.scopus.com/inward/record.url?scp=85196202691&partnerID=8YFLogxK

U2 - 10.1111/bph.16470

DO - 10.1111/bph.16470

M3 - Review

C2 - 38877789

AN - SCOPUS:85196202691

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

ER -

ID: 396860135